EFFECTOR THERAPUTCS INC by eFFECTOR Therapeutics, Inc. Financials - Benzinga

EFFECTOR THERAPUTCS INC by eFFECTOR Therapeutics, Inc.

EFTROTCEM

Trade with Public

Trade with Public

$0.00080

-0.18-99.56%

Last update: Sep 2, 1:36 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare

EFFECTOR THERAPUTCS INC by eFFECTOR Therapeutics, Inc. Financials

EFFECTOR THERAPUTCS INC by eFFECTOR Therapeutics, Inc. (EFTR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
eFFECTOR Therapeutics Q1 2024 GAAP EPS $(2.16) Beats $(2.17) Estimate; Reports Cash Runway Into Q1 Of 2025

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of $(2.17) by 0.46 percent.

Benzinga Newsdesk

Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03.

Avi Kapoor

Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P 500 also rose, gaining, 0.75% to 5,250.72.

Avi Kapoor

Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 39,259.15 while the NASDAQ rose 0.85% to 16,411.43. The S&P 500 also rose, gaining, 0.67% to 5,246.15.

Avi Kapoor

PRO
eFFECTOR Therapeutics Cash, Cash Equivalents, And Short-Term Investments Totaling $18.4M As Of December 31, 2023; Anticipates That It Will Be Sufficient To Fund Operations Into Q1 Of 2025

Fourth Quarter and Full Year 2023 Financial ResultsCash Position and Guidance: The company had cash, cash equivalents, and short-term investments totaling $18.4 million as of December 31, 2023, compared to $26.3 million

Benzinga Newsdesk

eFFECTOR Therapeutics Q4 EPS $(3.42) Misses $(1.65) Estimate

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(3.42) per share which missed the analyst consensus estimate of $(1.65) by 107.27 percent. This is a 37.82 percent increase over losses of $(5.50) per

Happy Mohamed